Endocrine and bone
Dopamine agonists (for pituitary tumours)
Drugs that stimulate D2 receptors on lactotrophs, suppressing prolactin and shrinking prolactinomas; first-line treatment for prolactin-secreting pituitary adenomas.
Mécanisme d’action
- Dopamine from the hypothalamus normally inhibits prolactin release through D2 receptors on lactotroph cells.
- Cabergoline and bromocriptine activate these receptors.
- Prolactin falls and prolactinoma cells shrink, often relieving pressure on the optic chiasm; they also reduce growth hormone in some acromegaly.
Cibles moléculaires
- Dopamine D2 receptor (pituitary lactotrophs): Agonist
Médicaments : Dopamine agonists (for pituitary tumours)
- Cabergoline (Long-acting; better tolerated.)
- Bromocriptine
Indications thérapeutiques
- Prolactinoma (prolactin-secreting pituitary adenoma), including macroadenomas
- Hyperprolactinaemia
- Acromegaly, as an add-on
Maladies traitées
Effets indésirables
- Nausea, dizziness and postural hypotension
- Impulse-control disorders
- Cardiac valve fibrosis with high doses over long periods
Contre-indications selon le terrain
- Rheumatic heart disease (Avec précaution): Activation of 5-HT2B receptors can thicken the valves.
- Psychotic illness (Avec précaution): Dopamine agonism can worsen psychosis.
Sujets liés
Rédigé d’après
- Lippincott Illustrated Reviews: Pharmacology, 7th ed., Ch. 23, Pituitary and Thyroid, Prolactin and dopamine agonists
- Basic & Clinical Pharmacology (Katzung), 14th ed., Ch. 37, Hypothalamic & Pituitary Hormones, Dopamine agonists
Ressource pédagogique. Ne constitue pas un avis, un diagnostic ou un traitement médical.